Groundbreaking ev-302 trial significantly extends overall survival and progression-free survival in patients treated with padcev® (enfortumab vedotin-ejfv) and keytruda® (pembrolizumab) in first-line advanced bladder cancer

Bothell, wash. & tokyo--(business wire)--seagen inc. (nasdaq: sgen) and astellas pharma inc. (tse:4503 “astellas”) today announced results from the phase 3 ev-302 clinical trial (also known as keynote-a39) for padcev® (enfortumab vedotin-ejfv) in combination with keytruda® (pembrolizumab) versus chemotherapy. the combination improved overall survival (os) and progression-free survival (pfs) with statistically significant and clinically meaningful results in patients with previously untreated lo.
SGEN Ratings Summary
SGEN Quant Ranking